Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Incidence, risk factors, and prediction model of piperacillin/tazobactam-associated hypokalemia in neonates.

Therapeutic advances in drug safety·2026
Same author

Genetic Variations in the M6A Modification Pathway as Potential Predictors of Imatinib Secondary Resistance in Gastrointestinal Stromal Tumors.

Journal of clinical medicine·2026
Same author

Application of diamondoids in source and maturity evaluation of light oil: a case study from the Kuqa Depression of the Tarim Basin, NW China.

Scientific reports·2026
Same author

Comparative Effectiveness and Modality-Dependent Prognostic Value of Pathological Response Following Neoadjuvant Therapy for Locally Advanced Gastric Cancer.

Cancer medicine·2026
Same author

Metabolic signatures and predictive biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study.

Cancer treatment and research communications·2026

Related Experiment Video

Updated: Jul 7, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA

Yongfeng Zhu1, Yanbin Zeng2, Wanlong Lin2

  • 1Department of Gastric Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

Cancer Investigation
|July 5, 2026
PubMed
Summary

Imatinib treatment can trigger immune-related adverse events, including organ dysfunction and inflammatory conditions like necrotizing panniculitis. These events show variations across patient demographics and occur later in the treatment course.

Keywords:
FAERSImatinibImmune-RelatedPanniculitis

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Experiment Videos

Last Updated: Jul 7, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Area of Science:

  • Pharmacovigilance
  • Immunology
  • Oncology

Background:

  • Imatinib may impact immune pathways, leading to adverse events (AE) with immune involvement.
  • Systematic characterization of imatinib-associated immune-related AEs is limited.

Purpose of the Study:

  • To systematically characterize immune-related adverse events associated with imatinib using real-world data.
  • To identify potential immune-mediated safety signals of imatinib.

Main Methods:

  • Analysis of FDA Adverse Event Reporting System data (2004-2024) for imatinib-suspected reports.
  • Identification of immune-related AEs using MedDRA queries and disproportionality analyses (ROR, PRR, MGPS, BCNN).

Main Results:

  • 74 safety signals identified in 15,748 patients, including organ dysfunction (liver, kidney, lung).
  • High-signal immune-related events included necrotizing panniculitis, inclusion body myositis, polyserositis, and lupus erythematosus.
  • Signals demonstrated heterogeneity across sex and age, often appearing mid-to-late in treatment.

Conclusions:

  • Imatinib is linked to various immune-mediated safety signals.
  • Observed age and sex heterogeneity warrants further investigation.
  • Prospective and mechanistic studies are recommended to elucidate these findings.